Changes in the vascular system of the brain may significantly contribute to the onset and progression of dementia and to the development of a chronic neurodegenerative process. In contrast to the neurocentric view, which proposes that changes in chronic neurodegenerative disorders, including AD, can be attributed solely to neuronal disorder and neuronal dysfunction, the neurovascular concept proposes that dysfunction of non-neuronal neighboring cells and disintegration of neurovascular unit function may contribute to the pathogenesis of dementias in the elderly population, and understanding these processes will be crucial for the development of new therapeutic approaches to normalize both vascular and neuronal dysfunction. In this review, I discuss briefly the role of vascular factors and vascular disorder in AD, the link between cerebrovascular disorder and AD, the clearance hypothesis for AD, the role of RAGE (receptor for advanced glycation end products) and LRP (low density lipoprotein receptor related protein 1) in maintaining the levels of amyloid ␤-peptide (A␤) in the brain by controlling its transport across the blood-brain barrier (BBB), and the role of impaired vascular remodeling and cerebral blood flow dysregulation in the disease process. The therapeutic strategies based on new targets in the AD neurovascular pathway, such as RAGE and LRP receptors, and on a few selected genes implicated in AD neurovascular dysfunction (e.g., mesenchyme homeobox gene 2 and myocardin) are also discussed.
INTRODUCTION
Several epidemiologic studies, including the large population-based Rotterdam study, 1, 2 have suggested that vascular risk factors might be responsible for cognitive decline in the elderly population. Old age, atherosclerosis, stroke, hypertension, transient ischemic attacks, cardiac disease, the ⑀4 allele of the apolipoprotein E gene, elevated homocysteine levels, hyperlipidemia, metabolic syndrome, obesity, and diabetes are among the risk factors for both vascular dementia and Alzheimer's disease (AD). [3] [4] [5] [6] It remains unclear whether controlling vascular risk factors, vascular brain disorder, and metabolic syndrome in early-diagnosed AD individuals will prevent progressive cognitive decline and dementia.
Progressive cognitive decline in AD is associated with neurovascular dysfunction, 3, 4 chronic neurodegenerative process, accumulation of neurotoxic amyloid ␤-peptide (A␤) on blood vessels and in brain parenchyma, [7] [8] [9] intraneuronal lesions and neurofibrillary tangles (NFT), 10 -12 and vascular deposition of amyloid resulting in cerebral amyloid angiopathy (CAA). 13, 14 Whether neurovascular dysfunction and vascular lesions precede a chronic neurodegenerative process, as suggested by a number of recent studies reviewed elsewhere, 15 or if they develop in response to neurodegeneration is controversial and has been a subject of many debates. However, not knowing the exact relationship between vascular and neuronal lesions in AD makes it more difficult to develop new therapeutic approaches for treating cognitive decline, especially in AD cases with prominent cerebrovascular and metabolic comorbidity.
ROLE OF BRAIN ISCHEMIA
Large cerebral arteries in AD do not develop CAA, but are frequently affected by atherosclerosis. 16, 17 The Nun Study 18 found that cerebrovascular disease determines the presence and severity of AD, and that demented AD individuals with one or two lacunar infarcts have a much steeper drop in cognitive function than do individuals with no brain infarcts, irrespective of the number of NFT in neocortex. The Rotterdam Scan Study, 19 a prospective, population-based study with 1015 patients, demonstrated that silent brain infarcts detected on magnetic resonance imaging (MRI) doubled the risk for dementia in elderly people, with a hazard factor of 2.26. The Rotterdam Study, with 1730, subjects found that cerebral hypoperfusion preceded the onset of clinical dementia and that reductions in cerebral blood flow (CBF) velocity occurred before cognitive decline and before hippocampal and amygdalar atrophy were documented on MRI. 2 Nonetheless, the exact pathway or pathways by which atherosclerosis and arteriolosclerosis contribute to cognitive decline, and the relationship between vascular brain damage, white matter hyperintensities on MRI, and cognitive decline, are still not completely understood. 20 Figure 1 illustrates possible pathways by which atherosclerosis may lead to dementia. Whether progression of vascular disorder and dementia in AD could be controlled by a new class of agents exerting combined anticoagulant, anti-inflammatory and neuroprotective activities in the ischemic brain, such as activated protein C (APC), 21 remains to be explored. In rodents, ischemia increases A␤ production, 3 accumulation of hyperphosphorylated tau in cortical neurons, and filament formation similar to that present in human neurodegenerative tauopathies and in AD, 22, 23 which suggests that hypoperfusion may generate neuropathological changes similar to those seen in AD individuals. Amyloid ␤-peptide is a potent vasoconstrictor in brain. 24 In mice expressing A␤-precursor protein (App), reductions in endothelium-dependent regulation of cortical microcirculation 25 and CBF dysregulation in response to brain activation have been reported prior to neuropathological changes. 26, 27 Similarly, neurovascular uncoupling, reductions in CBF, and low brain uptake of glucose have been shown in sporadic AD prior to cognitive decline. 28 -30 
CLEARANCE HYPOTHESIS FOR AD
Most AD cases (ϳ99%) present with late onset (i.e., Ͼ65 years of age) and without clear evidence of genetic transmission. 31 Late-onset AD individuals do not normally have increased production of A␤. Instead, A␤ likely accumulates in the brain of AD individuals because of deficient clearance from brain, [32] [33] [34] [35] as illustrated in Figure 2 . Recent evidence suggests that plaques are generated on blood vessels due to faulty A␤ clearance across the blood-brain barrier (BBB) or during its transport by passive diffusion across Virchow-Robin perivascular arterial spaces. 15 Amyloid ␤-peptide is central to the development of brain pathology in AD. [7] [8] [9] 12, 33, 36, 37 Patients with sporadic AD and familial AD (FAD; Ͻ1% of all AD cases) typically develop focal increases in brain A␤ levels midway through the disease process or at a later stage. Elevated A␤ levels in brain generate neurotoxic A␤ oligomer species, which may disrupt normal brain function 37 or lead to A␤ deposits in the form of senile plaques. In murine models of AD, such as APP-overexpressing mice with Swedish mutation (APPsw ϩ/Ϫ ) and transgenic APP mice harboring vasculotropic Dutch, Iowa, and Swedish triple APP mutations, dense plaques initially develop on blood vessels or as classical CAA. 38 -40 In more than 80% of AD cases , the pial and intracerebral arteries are affected by CAA.
14 Pathogenic levels of vasculotropic mutant forms of A␤ (e.g., Dutch, Iowa, Arctic, Flemish, Italian) accelerate degeneration of the vessel wall, thus contributing to hemorrhagic strokes, as in familial forms of AD. 13 How we might prevent A␤ accumulation by accelerating its clearance from brain is an emerging area of research, one that holds promise for the development of new future therapies for AD.
RAGE AND LRP REGULATE A␤ BLOOD-BRAIN BARRIER TRANSPORT

RAGE
The receptor for advanced glycation end products (RAGE) is normally expressed at low levels in brain, except for the endothelium of brain capillaries and small arterioles (A. Sagare, R. Deane, R.D. Bell, and B.V. Zlokovic, unpublished observations). However, under pathophysiologi- cal conditions such as those associated with the accumulation of RAGE ligands on blood vessels (e.g., deposition of proteins modified by glycation and oxidation, whether AGE proteins or A␤), the expression of cerebrovascular RAGE is increased. In AD and AD models, RAGE expression increases by several-fold in affected cerebral vessels and in microglia and neurons. [41] [42] [43] [44] [45] [46] RAGE binds different forms of A␤, and its reaction with A␤ at the luminal membrane of the BBB (FIG. 3) mediates 1) re-entry of circulating A␤ into the brain across the BBB, followed by A␤ binding to neurons; 2) NF-B-dependent activation of endothelium with expression of proinflammatory cytokines and adhesion molecules; and 3) secretion of endothelin-1 resulting in CBF reductions. In addition to the observations in mice and rats, transport of A␤ peptides from blood to brain across the BBB has been shown in other species, including guinea pigs and nonhuman primates. 47, 48 Compared with other small peptides, such as vasopressin or enkephalins, 49, 50 transport of A␤40 across the mouse BBB was two-to threefold faster, although it was only a fraction of the rate determined for amino acid transport either across the BBB or the choroid plexus. 51, 52 RAGE is an important therapeutic target in AD. RAGE-A␤ interaction on neurons can kill neurons directly by producing oxidative damage or indirectly by activating microglia. 41 Inhibition of RAGE-A␤ interaction in the affected blood vessels blocks A␤ influx across the BBB and the associated oxidant stress and neuroinflammation. 43 RAGE and A␤ blockers are currently being tested in AD patients for safety and efficacy. A double-blind, placebo-controlled, randomized, multicenter study conducted under the Alzheimer's Disease Cooperative Study to evaluate the efficacy and safety of 18 months of treatment with PF-04494700 (TTP488) in participants with mild-to-moderate Alzheimer's disease began patient enrollment in December 2007.
LRP
Low density lipoprotein receptor related protein 1 (LRP), a member of the LDL receptor family, is a major clearance receptor for A␤ at the BBB. 53 A␤ binding to LRP is the first step in A␤ clearance from brain mediated by transvascular A␤ transport across the BBB 39, [53] [54] [55] (FIG. 3) . Substitution at codon 22 of LRP, as in Dutch type FAD, reduces clearance of A␤ from the CSF and brain into blood. 56 Reduced expression of LRP was found during normal aging in rodents, nonhuman primates, and in AD individuals associated with positive staining of cerebral vessels for A␤40 and A␤42. 39, 45, 53 Mice with severely depleted LRP levels at the BBB develop A␤ accumulations when crossed with APPoverexpressing mice. 57 Binding of A␤ to apolipoprotein J and E and ␣2-macroglobulin critically alters A␤ clearance rates from the brain and can influence vascular and parenchymal accumulation of A␤. 35, 55 Finally, LRP mediates A␤ systemic clearance from the liver. 58 ␤-Secretase cleaves the N-terminal extracellular domain of LRP 59 and releases soluble LRP (sLRP) in plasma. Normally, sLRP binds 70% to 90% of A␤ in human plasma. 60 A␤ binding to sLRP is significantly reduced in late-stage cases of late-onset AD; this, in turn, may elevate brain A␤, because of reductions in the endogenous peripheral sink activity of sLRP. Recombinant LRP clusters can effectively sequester A␤ in AD plasma and in APPsw ϩ/Ϫ mice, promoting A␤ efflux from the mouse brain. 60 Thus, LRP fragments may have therapeutic potential as novel A␤ clearance agents or in sLRP replacement therapy for AD.
Mdr1a/Mdr1b null mice lack P-gp at the BBB and express lower levels of LRP in brain capillaries.
54
Mdr1a/Mdr1b null mice exhibit reduced clearance of A␤ from brain, whereas APP mice lacking P-gp have accelerated accumulation of A␤ and amyloid deposition. Thus, the Mdr1a and Mdr1b genes may influence A␤ clearance either directly through P-gp, indirectly through LRP, or through both.
IMPAIRED VASCULAR REMODELING
Reduced microvascular density, fragmented and atrophic string vessels, irregularity of capillary endothelial surfaces, reductions in the vessel diameter, thickening of
FIG. 3.
Transport equilibrium for amyloid ␤-peptide (A␤) at the blood-brain barrier (BBB). The cell surface LRP on the abluminal membrane binds different forms of A␤ (e.g., monomers, oligomers, aggregates) and initiates A␤ transcytosis across the BBB followed by its export into the circulation. In the case of A␤ overload, LRP (low density lipoprotein receptor related protein 1) loses its normal protein conformation and undergoes the accelerated proteosomal degradation. A␤ efflux is influenced by its transport binding proteins in the brain, such as apolipoproteins E and J (apoE, ApoJ), or ␣2-macroglobulin (␣2M). ␤-Secretase (BACE) cleaves the N-terminus extracellular domain of LRP1, which generates a soluble form of LRP (sLRP). In human plasma, more than 70% of A␤ is normally bound to sLRP. Native plasma sLRP is a major endogenous peripheral sink agent for A␤. The remaining A␤ in the plasma is bound to other A␤-transporting proteins (e.g., apoJ). A small fraction of plasma A␤ is free. On the luminal membrane, free A␤ that escapes the sLRP surveillance in the blood interacts with the receptor for advanced glycation end products (RAGE). A␤-RAGE interaction mediates re-entry of A␤ from blood to brain (influx), and activates the endothelium through reactive oxygen species (ROS)-induced nuclear translocation of NF-B. This triggers secretion of proinflammatory cytokines, such as interleukin-6 (IL-6), tumor-necrosis factor-␣ (TNF-␣), the expression of adhesion molecules at the BBB, such as intercellular adhesion molecule 1 (ICAM1) and vascular cell adhesion molecule (VCAM), and secretion of endothelin-1, a suppressor of blood flow. capillary basement membranes, and collagen accumulation in basement membranes have been described in AD. 61, 62 It has been suggested that the degeneration of brain capillary endothelium seen in AD and AD models may reflect aberrant sprouting angiogenesis in response to chronic brain hypoxia. 15 A recent report found extremely low levels of expression of the mesenchyme homeobox gene 2 (MEOX2) in the BBB of AD individuals. 63 MEOX2 normally regulates vascular cell differentiation and repair, and its expression in the adult brain is restricted to the vascular system. Low levels of MEOX2 in AD endothelium mediate abnormal responses to angiogenic factors such as vascular endothelial growth factor, resulting in premature vessel regression, reduced resting CBF and improper formation of the BBB. 63 Low levels of MEOX2 also promote proteasomal degradation of LRP, which lowers the A␤-clearing capability at the BBB, thus leading to A␤ accumulation on the blood vessels. Accumulation of A␤ on the abluminal membrane of the blood vessels is antiangiogenic, which amplifies the reductions in microcirculation in AD models 64, 65 and possibly in AD. Thus, aberrant angiogenesis has an amyloidogenic effect at the BBB 66 And could represent an important novel target IN AD.
Recent studies have also shown that the expression of two transcription factors that control differentiation of vascular smooth muscle cells (VSMC), the serum response factor (SRF) and myocardin (MYOCD), is increased in AD, resulting in a hypercontractile phenotype in small cerebral arteries associated with brain hypoperfusion and diminished CBF responses to brain activation. 67 These events may also contribute to the hypoperfusion observed in AD brains. Thus, drugs that specifically disrupt SRF-MYOCD interaction in small brain vessels may hold potential to improve brain perfusion and CBF dysregulation in AD.
CONCLUSIONS
Recent clinical observations provide strong evidence for the link between cerebrovascular disease and AD, cognitive decline, or both. Here, we have briefly reviewed changes in the expression of key vascular receptors and genes in brain capillaries and small cerebral arteries in AD and in AD models that may lead to focal vascular and brain accumulations of A␤, reductions in the resting CBF, attenuated CBF responses to brain activation, and focal neuroinflammatory response. The activation of the neurovascular pathogenic pathway may, in turn, compromise synaptic and neuronal functions, ultimately leading to neuronal damage with accumulation of intraneuronal tangles, neuronal loss, and dementia. The early molecular changes within the neurovascular pathway may offer new therapeutic targets for controlling progression of dementia in AD, including therapies based on the receptors RAGE and LRP or on genes implicated in the neurovascular AD model, such as MEOX2, or SRF and MYOCD.
